To evaluate the efficacy and side effects of an herbal formulation to promote weight loss, as compared to placebo. DESIGN: 12-week multicenter double-blind, placebo-controlled, randomized parallel groups design. Study conducted at three clinical sites in New York State. Subjects were randomized to receive either the 'active' product or a 'placebo' supplement for 12 weeks. Minimal steps were taken to influence lifestyle changes with regard to diet or exercise. SUBJECTS: 102 overweight/obese (30oBMIr39.9 kg/m 2 ) volunteers between the ages of 18 and 65 y. MAIN OUTCOME MEASURES: Weight, percent body fat, fat mass, waist circumference, BMI, blood pressure, and pulse measured at 2 days, 1 week, 2 weeks, 4 weeks, 8 weeks, and 12 weeks postrandomization. RESULTS: Subjects receiving the 'active' treatment experienced, on average, an additional 1.5 kg of weight loss compared with subjects receiving the placebo. In addition, subjects receiving the 'active' treatment experienced greater reductions in BMI and waist circumference over the 12-week period. No differences were observed with respect to percent body fat, fat mass, diastolic or systolic blood pressure, pulse, the occurrence of any adverse event, or the occurrence of any presumed treatment-related adverse event. Testing of the study product by two independent laboratories indicated that it had only approximately half of the intended amount of ephedrine alkaloids and caffeine. CONCLUSIONS: Over the 12-week trial, subjects on the active treatment experienced significantly greater weight loss than subjects on placebo, without an increase in blood pressure, pulse, or the rate of adverse events. These benefits were achieved in the absence of any lifestyle treatment to change dietary or exercise behavior and with lower doses of ephedrine alkaloids and caffeine than those commonly utilized.
Introduction
There is currently an increasing prevalence of obese and overweight individuals in this country. More than half of US adults are overweight and approximately one-third are obese. 1 Obesity is associated with a variety of adverse conditions such as cardiovascular disease and noninsulindependent diabetes mellitus (NIDDM) 2 and with decreased longevity. 3, 4 Short-term weight loss is associated with improvements in health and reduced risk factors for morbidity and mortality. 5 Medium-term (4 y) weight loss is associated with markedly reduced risk of new onset NIDDM. 6 An emerging body of research suggests that, when analyses are confined to obese individuals who profess an intention to lose weight, subsequent weight loss is associated with no harmful effects and perhaps a very modest decrease in mortality rate. 7, 8 Nevertheless, weight loss is difficult to maintain, and only approximately one in five people who try to lose weight succeed in maintaining all weight initially lost or a clinically meaningful weight loss of 9-11 kg for 3-5 y. 9 Currently, only one FDA-approved OTC drug for weight loss exists (Benzocaine) and is not widely used, widely studied, or widely thought to be effective. 10 Several prescription drugs exist, but they are relatively expensive, 11 of modest efficacy, 12 and in some instances have raised safety concerns. 13 This has led many people to use dietary supplements for weight loss. 14 Perhaps, the best-known class of weight loss products are those which contain ephedra alkaloids from herbal sources. 15 However, the use of such products remains controversial (see addendum) 16 and it is therefore critical that as many data as possible be brought to bear on the safety and efficacy of such products. Thus, there is a great need to evaluate additional agents for weight loss and to conduct rigorous state-of-the-art clinical trials to evaluate the safety and efficacy of potential therapeutics. In addition, it has been shown that ephedrine and caffeine have synergistic effects on thermogenesis 17 and weight loss. 18 For reviews of the pharmacodynamics behind this synergy, see (Dulloo; 19 Greenway and Huber 20 ). This study is intended to examine the efficacy and safety of a potential antiobesity product that is a combination of Ma huang (containing ephedrine), Kola nut (containing caffeine), White willow bark (containing salicin), and other herbal components.
Methods

Study design
The study was a multicenter placebo-controlled, randomized, parallel-group, 12-week, longitudinal trial designed to compare the weight loss efficacy and side-effects of an herbal formulation to that of a placebo. Subjects were randomly assigned to receive either the 'active' product or a placebo supplement (see Figure 1 for a study flow chart). Secondary outcomes were percent body fat, BMI, waist circumference, blood pressure, pulse, and serum lipid concentrations.
Subjects
Overweight/obese persons between the ages of 18 and 65 y with body mass index (BMI; kg/m 2 ) between 30.0 and 39.9
were enrolled in this trial (men: n ¼ 14 and women: n ¼ 88). Exclusion criteria were: a maintained weight loss 410 kg in the preceding 3 months; meals not eaten at regular intervals; participation in another investigational study within the past 30 days; a history of alcohol or drug abuse within the past year; females pregnant, lactating, or fertile and unwilling to use a method of birth control acceptable to the investigator; a significant history or current presence of diabetes mellitus or hypertension (systolic BP4140 and/or diastolic BP490); clinically significant endocrine, hepatic, renal, or cardiovascular disease; a history of sleep disorders, clinical depression or other psychiatric conditions; abnormal ECG or laboratory values; the presence of any medical condition or the use of any medication that could have interfered with the conduct of the study or placed the prospective subject at risk; or known allergy or sensitivity to any of the 'active' or 'placebo' product ingredients. (Protocol violations occurred when two subjects were enrolled and randomized to the active group in error. Both subjects answered 'No' to the question 'Female subject is not currently receiving or planning to receive any assisted reproductive technologies capable of producing pregnancy (whether in a same-sex relationship, single or abstinent, or subfertile/infertile)'. Since complete data was collected for both subjects and no major differences in conclusions were observed when these subjects were or were not included in the analyses, they are included in all analyses reported here.) The study was approved by a legally constituted IRB located at RTL, Inc. in Great Neck, New York on May 2, 2001 , and all subjects signed informed consent forms. Prospective subjects were determined to be in good general health and appropriate for study participation based on the results of medical history, physical examination, 12-lead electrocardiogram, and laboratory testing, all interpreted by the study physician.
Treatment conditions
The 'active' study product was a potential antiobesity product that contained Ma huang (containing ephedrine), The study design was intended to emulate 'real-life' conditions under which the study product is administered. Hence, minimal steps were taken to influence other lifestyle changes. At the time of randomization, subjects were given pamphlets that described lifestyle modifications that would achieve a healthier lifestyle. However, no additional counseling with regard to modifications of dietary or exercise behaviors was provided during the course of the study. Thus, this study assessed the efficacy of the study product in a group of patients given the freedom to eat whatever they desired and not encouraged to make other modifications beyond taking the tablets in the appropriate manner (two caplets taken three times daily).
Measures
Study subjects returned to the clinics at 2 days, 1, 2, 4, 8, and 12 weeks postrandomization. At each visit, compliance assessments were performed and subjects were given a sufficient supply of the appropriate study product to permit dosing until the time of the next scheduled visit.
Height measurements were obtained at the randomization visit. At randomization and each subsequent visit, brief physical assessments were repeated on all subjects, including measurements of weight, vital signs, and girth at the waist. From the height and weight measurements, BMIs were calculated. At the randomization visit and 12 week followup visit, electrocardiograms (ECGs) were performed, and blood and urine samples were collected for routine laboratory analyses. In addition, serum lipid levels were obtained at baseline and study conclusion.
Height was measured within 0.1 in, using a unit attached to the scale, and then converted to cm. Body weight was measured within 0.1 kg using a standardized calibrated scale. Body fat determinations were performed using a Health Management System 1000 (Bioanalogics; Beaverton, OR, USA) bioimpedance analyzer (See: http://www.bioanalogics. com/validity.htm for validity information). All anthropometric measurements were taken using the Gullick 2 Anthropometric Tape Measure Model 67020, manufactured by Country Technology, Inc. Waist measurements were completed as per NHANES III Protocol. Blood pressure was measured after at least 5 min of rest using a standard mercury sphygmomanometer and appropriately sized cuffs, according to the guidelines of the American Heart Association.
Adverse events (AEs) were assessed by the investigator. For each AE encountered, the study physician classified the relationship between the AE and the study product as None, Possible, Probable, or Definite. Any AE classified by the study physician to have at least a possible relationship to treatment was presumed to be a treatment-related adverse event.
Statistical analysis
The principal aim of the analysis was to compare the effects of the 'active' product and placebo over time on the primary and secondary outcomes. Because dropouts were observed over the course of the study, the primary analysis consisted of an intent-to-treat (ITT) repeated measures mixed model 22, 23 examining weight loss over the course of the study. As opposed to traditional repeated measures techniques, mixed models permit the inclusion of subjects with missing values for some visits. These mixed models examined linear and quadratic trends over time separately for group assignment (control or active), the main independent variable of interest. Baseline weight (at visit 2) entered the model as a covariate. In order to reduce the problem of multicollinearity, often present in polynomial models, we subtracted the integer value closest to the mean values of time and baseline weight from each individual value. Furthermore, an examination of the raw data suggested that measurements observed over time within a patient were correlated and that the variation in measurements increased over time. In order to account for this, random intercepts and slopes were fit for each patient. The use of a random coefficient for each patient allows for the variation to differ between subjects and accounts for the fact that measurements observed over time within a patient are correlated. This standard random coefficients model can also be thought of as utilizing a random intercept for each subject. The addition of a random slope as well accounts for the fact that the variation in measurements within a subject tends to increase linearly over time. We considered more complex covariance structures that allowed the variation in measurements within a subject to increase in a quadratic or cubic fashion over time. Although these models provided a slightly improved fit over the model that allowed variation to increase linearly with time, the overall conclusions were not affected. Hence, we report the results from the model with a random intercept and slope for parsimony.
By utilizing mixed models with random intercepts and slopes for each patient, we were then able to simultaneously address the following questions in the final model:
Was there a difference in immediate 2-day weight loss, 1-week weight loss, and 12-week weight loss among subjects Ephedra and caffeine in absence of lifestyle treatment CS Coffey et al receiving the active product vs subjects receiving the placebo?
Was there a difference in the trend of weight loss over the entire course of the study among subjects receiving the active product vs subjects receiving the placebo, that is, was there a time by treatment interaction?
Hence, this mixed model time by treatment interaction analysis allowed us to examine not only the amount of weight loss at the end of the study, but also how that weight loss came to be (ie was the weight loss rapid and then maintained? slow but consistent from week to week? etc).
Secondary efficacy analyses to compare 2-day, 1-week, and 12-week changes in percent body fat, fat mass, body mass index, and waist circumference were performed in a similar manner. Finally, the percentage of patients in the two groups achieving reductions of 41 and 45% from baseline weight at the conclusion of the 12-week study period were compared using the Pearson w 2 -test. In addition, we conducted a last observation carried forward (LOCF) analysis to examine the impact of the 11 subjects who dropped out before the conclusion of the study. The conclusions from this LOCF analysis were identical to the completers only analysis reported above, hence we report only the latter analysis here. The 12-week changes in serum lipid values were examined using the nonparametric Wilcoxon test. For one subject, a member of the investigative team determined that the initial lipid baseline values should be repeated since these initial laboratory values were nonfasting. Hence, the repeated laboratory values were used as baseline values for analytic purposes.
With respect to side effects, we also examined changes in systolic blood pressure, diastolic blood pressure, and pulse using mixed model techniques in the same manner as with the efficacy analysis. We also used logistic regression methods to compare both the percentage of subjects having any adverse event (AE) and the percentage of subjects having any putatively treatment-related adverse events (PTRAE) in the two groups. All significance tests were conducted at the two-tailed 0.05 alpha level.
Results
Descriptive statistics
Baseline characteristics of subjects enrolled in the trial are shown in Table 1 . As expected due to the randomization scheme, subjects in both groups had similar characteristics upon entering the study. Possible exceptions included a slightly higher (though not statistically significant) percentage of subjects in the active group with high BMI (Z35) at baseline, past gastrointestinal and endocrine conditions, and abnormal skin condition during the baseline medical exam. In all, 81% of subjects were White Non-Hispanic, 6% were Hispanic, 11% were Black Non-Hispanic, and 2% were other or unknown. Compliance for an individual subject was determined by taking the ratio of the cumulative number of tablets actually taken to the cumulative number of tablets that should have been taken over the course of the study and was expressed as a percentage. Mean group compliance was above 95% for both groups.
A total of eight patients in each group (16 total) discontinued the study. In the control group, three subjects discontinued due to an adverse event (Emesis, Elevated Blood Pressure, and Hypothyroidism), three subjects withdrew consent, and two subjects were lost to follow-up. In the active group, two subjects discontinued due to an adverse event (Compression Fracture of L1 and Elevated Blood Pressure), one subject was unable to meet protocol criteria ('Subject was unable to return to study site for Visit 8'), one subject was withdrawn for a protocol violation or noncompliance ('Subject missed visit 7 and has been off product since 11/30/01'), two subjects withdrew consent, and two subjects were lost to follow-up. However, it should be noted that three of these subjects who discontinued returned for a final evaluation during a time window which provided a valid week 12 measurement. Table 2 summarizes each of the efficacy outcome variables between baseline and 2 days, 1 week, and the conclusion of the study (12 weeks), respectively, for subjects in the active and control groups. For each variable, the table displays unadjusted mean decreases and standard deviations as well as model adjusted mean decreases, standard errors, and the P-values for comparing the two groups. The model adjusted means correspond to the final mixed model incorporating linear and quadratic effects to measure the effect over time for both groups, random intercepts and slopes for each subject to account for correlations over time and increasing Ns differ because some measures were missing and because two ineligible participants were randomized to the active group.
Efficacy analyses
Ephedra and caffeine in absence of lifestyle treatment CS Coffey et al variation from visit to visit within a subject, and adjusts for baseline measurements. The table also presents the P-values for the test of a time by treatment interaction from the mixed model, that is, a test of differences in the trend for changes from baseline over time for the two groups. Note that positive numbers indicate decreases from baseline while negative numbers indicate increases from baseline.
Weight loss. Figure 2 displays the mean decrease in weight from baseline for both groups over the course of the six study visits. The points connected by dashed lines represent the observed decreases over the course of the study. The points connected by solid lines represent predicted values from the final mixed model. Measurements for the active and control groups are represented by green and red lines, respectively. There was a significant initial weight loss at 2 days in both the control (0.39 kg70.12, P ¼ 0.002) and active groups (0.47 kg70.12, P ¼ 0.0001), but there was no statistically significant difference in the amount of initial weight loss between the two groups (P ¼ 0.64). No additional weight loss over time was observed in the control group (P ¼ 0.79); hence, the initial weight loss observed in the control group appears to be due to a placebo effect. On the contrary, there was a highly significant effect of time on weight loss in the active group with the amount of weight loss increasing linearly over the course of the study (P ¼ 0.0001). As a consequence, there is a highly significant time by treatment interaction observed with respect to weight loss (P ¼ 0.007) and a highly significant difference in the amount of weight loss observed in the two groups at the conclusion of the study (2.10 kg 7 0.35 for the active group vs 0.46 kg70.37 for the control group, P ¼ 0.002). Furthermore, as is to be expected since the height of the patients remains unchanged during this trial, we obtained similar results when we conducted the analysis using BMI as the outcome.
Percent body fat. There was a significant initial reduction in percent body fat at 2 days in the control group (0.72%70.31, Reductions in percent body fat continued in a linear manner over time for both groups, although the rate of reduction seemed slightly higher in the active group (P ¼ 0.002) than in the control group (P ¼ 0.09). As a consequence, no statistically significant difference in reduction of percent body fat in the two groups was observed at the conclusion of the study (1.13%70.40 for the active group vs 1.59%70.41 for the control group, P ¼ 0.42).
Fat mass. The results for the analyses with fat mass serving as the outcome of interest mirror the results obtained when using percent body fat as the outcome. Most notably, there was no statistically significant difference in reduction of fat mass in the two groups at the conclusion of the study (1.61 kg70. 45 for the active group vs 1.80 kg70.43 for the control group, P ¼ 0.76).
Waist circumference. There was a significant initial reduction in waist circumference at 2 days for the active (0.47 cm70.23, P ¼ 0.04) but not the control group (0.24 cm70.24, P ¼ 0.32), although there was no statistically significant difference in the amount of initial reduction in waist circumference between the two groups (P ¼ 0.49). There was a highly significant effect of time on reduction of waist circumference in both the active (Po0.001) and control (P ¼ 0.002) groups, with the reduction in waist circumference increasing over the course of the study. However, a significant time by treatment interaction was observed (P ¼ 0.01) due to the fact that the rate of reduction in waist circumference was linear in the active group, but quadratic in the control group (ie linear at first, then leveling off). This was evidenced by the fact that little additional reductions in waist circumference were observed in the control group after the first week, while the reductions in waist circumference continued throughout the 12-week study period for the active group. As a consequence, there was no difference in the reduction of waist circumference observed in the two groups 1 week into the study (0.6570.22 for the active group vs 0.4170.23 for the control group, P ¼ 0.45) but a highly significant difference was observed at the conclusion of the study (2.57 cm70.42 for the active group vs 0.91 cm70.43 for the control group, P ¼ 0.006).
Responder rates. Table 3 summarizes the percentage of baseline weight lost at the end of the 12-week period in the two groups. At the conclusion of the study, there was a statistically significant increase in the percentage of patients who lost greater than 1% of their initial body weight in the active group as opposed to the control group (69 vs 45%, P ¼ 0.02). However, there was no statistically significant difference between the two groups in the percentage of patients who lost greater than 5% of their initial body weight (15 vs 12%, P ¼ 0.62). This implies that while there was a greater response with regards to weight loss in the active group, the observed weight loss was relatively small when considered as a percentage of initial weight.
Serum lipid analyses
There were 'marginally significant' (defined as 0.05oPo0. 10) larger decreases in total cholesterol and triglycerides in the active group as compared to the control group. All other serum lipids showed no significant differences between the two groups.
Safety-related results
Systolic blood pressure, diastolic blood pressure, and pulse. Table 4 summarizes the change in systolic BP, diastolic BP, and pulse between baseline and 2 days, 1 week, and 12 weeks, respectively, for subjects in the active and control groups. As with the efficacy variables, the table displays unadjusted means and standard deviations as well as adjusted means, standard errors, and the P-values obtained from the final mixed model for comparing the two groups. However, it should be noted that this table presents changes from baseline in these variables rather than decreases. Hence, in this table, positive numbers indicate increases from baseline while negative numbers correspond to decreases from baseline. No significant time by treatment interaction was observed for systolic BP (P ¼ 0.76) and diastolic BP (P ¼ 0.49). Although the time by treatment interaction was not statistically significant (P ¼ 0.09), there was a marginally significant difference in change in pulse rates observed in the two groups at the conclusion of the study. However, this was primarily due to an observed decrease in pulse rates for the control group at 12 weeks (0.78 bpm71.15 for active group vs À2.32 bpm71.19 for control group, P ¼ 0.06).
Adverse events. Table 5 displays the distribution of the number of adverse events and treatment-related adverse events per person in the study sample for each treatment group. Of the 102 patients in the study, 78 (76%) suffered at least one AE and 30 (29%) suffered at least one PTRAE over the course of the study. There was no difference in the occurrence of any adverse event between the two groups (77% for active vs 76% for control, P ¼ 0.91). Similarly, there was no difference in the occurrence of any PTRAE between the two groups (33% for active vs 26% for control, P ¼ 0.46). Of the 78 subjects who experienced adverse events, 56 had multiple adverse events. Hence, a total of 196 adverse events observed over the course of this study. Of these, five 'serious' adverse events occurred in two subjects. One subject in the Ephedra and caffeine in absence of lifestyle treatment CS Coffey et al control group had three adverse events classified as serious: 'Exacerbated Depression', 'Atrial Fibrillation', and 'Exacerbation of Asthma'. However, none of these adverse events kept the subject from completing the study. One subject in the active group had two adverse events classified as serious: 'Low Back Pain' and 'Compression Fracture of L1', which forced this patient to discontinue the study.
Discussion
This 12-week weight loss trial comparing an active treatment to placebo indicated that the active treatment was associated with greater weight loss as well as greater reductions in other related health variables. There were no significant differences between the two groups in changes in percent body fat, diastolic blood pressure, systolic blood pressure, pulse, the occurrence of any adverse event, or the occurrence of any putatively treatment-related adverse event.
The results of this study seem quite clear and quite consistent with a growing body of literature on the effects of ephedra-containing products for weight loss.
14,24 Specifically, this study shows that a product containing ephedra, caffeine, and salicylic acid from herbal sources is effective in producing weight loss and does not produce commonly significant short-term adverse effects. Although one patient in the active treatment group withdrew due to elevated blood pressure, so too did one subject in the control group. Moreover, this study demonstrates that the study product was effective in a group of subjects who were not encouraged to make lifestyle modifications other than taking the study product as directed. These results suggest that subjects do not have to be jointly involved in a structured program to modify lifestyle in order to achieve the weight-loss benefits of the study product. Of course, combining the study product with a healthy diet and exercise program would be expected to increase the amount of weight loss.
With respect to clinical benefit, clearly longer term studies would be valuable. Results from the Diabetes Prevention Program (DPP) suggest that even moderate weight losses that are not fully sustained can confer marked health benefits. 6 Whether such benefits can be produced via long-term treatment with ephedrine-containing products remains to be demonstrated.
With respect to safety, our results are consistent with past research in showing no serious, deleterious consequences with the use of such products in controlled weight loss studies. Although this is an encouraging outcome, several points should be kept in mind. First, because our study was only 12 weeks in duration, it offers no direct evidence about any potential positive or negative effects associated with long-term usage. Second, our exclusion criteria and the nature of the study process are such that our sample cannot be presumed to be representative of the general population. Therefore, one can speculate that different results might be A number of safety concerns have been raised about the use of ephedrine-containing products. 16 At the same time,
there are also data to suggest that the closely related compound pseudoephedrine can be used widely with apparent safety. 25 There are also interesting data that, among
Fisher 344 female rats, long-term ingestion of ephedrine results in lower body weight and greater longevity. 26 These data suggest the possibility of important clinical benefits to use of ephedrine-containing products among obese persons. An important limitation of this study concerns the quality control of the product. As stated above, although the product was supposed to have 10 mg of ephedra alkaloids and 60 mg of caffeine per unit, testing of the product by two independent laboratories indicated that it only had roughly half that amount (4.15 mg ephedrine alkaloids; 25.3 mg caffeine) (Pinnacle Inc, personal communication, 2003). This is not entirely surprising given the results of Gurley et al. 27 It is noteworthy that the dose of ephedrine alkaloids that we used (B30 mg/day) is quite modest compared to doses of ephedrine previously used. The most common preparation used, based on Astrup's research, contains 20 mg ephedrine plus 200 mg caffeine three times a day. This is actually a reduction by 50% compared to the earlier Elsinore pill (40 mg ephedrine þ 100 mg caffeine), which was available in Denmark for a number of years. 20, 28 On the one hand, it can be taken as encouraging that we so clearly demonstrated efficacy even with such reduced doses of ephedrine alkaloids and caffeine. On the other hand, it is challenging to conduct the most rigorous of studies when manufacturing standards are not at a higher level. It also implies that our safety-related results can only be definitively taken to apply to the dose given and not to higher doses. Clearly, this suggests that greater standards for manufacturing control of such herbal products would be beneficial to ensure that the stated doses of the 'active' ingredients are correct. It also suggests the need for federal or other nonindustry funding of such studies so that protocols, including thorough checking the composition of the test product, can be run with a greater degree of rigor. In this regard, it should be noted, as one reviewer did, that it is not unheard of for herbal products to be adulterated or 'laced' with unlabeled ingredients (eg, Ku et al 29 ) . We operated under the assumption that the manufacturer's statements about active ingredients were accurate. However, in future research, it would be wise to test for this via an independent laboratory as was done here for the ephedrine and caffeine content.
In conclusion, we believe our results demonstrate the efficacy of the product tested and provide some reassurance with respect to its safety. These benefits were achieved in the absence of any enjoinder to lifestyle treatment to change dietary or exercise behavior and with lower doses of ephedrine alkaloids and caffeine than those commonly utilized. Our results are consistent with a body of literature but are also limited by being short-term, based on a modest number of subjects, and with a product containing a lower dose than expected. We believe that the latter points underscore the need for larger, longer term studies of pharmaceutical grade ephedrine for the treatment of obesity.
Addendum
As we completed writing this manuscript, the US Food & Drug Administration announced that 'The Food and Drug Administration (FDA) is alerting the public to its forthcoming determination that dietary supplements containing ephedra present an unreasonable risk of illness or injury, and should not be consumed. The agency has notified firms manufacturing and marketing these products that it intends to issue a final rule prohibiting their sale, which will become effective 60 days after its publication.' 30 Although products marketed as dietary supplements containing ephedra like the one tested herein will presumably not be available in the US in the near future, our results should still be of use to those in other parts of the world where such supplements may still be in use, to investigators considering designing studies of other dietary supplements for weight loss, to litigators working on cases involving alleged effects of ephedra-containing products, and to designers of new potential antiobesity products who wish to consider the effects of related products.
